Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set

FATE THERAPEUTICS INC

2022-Q2 EPS reported -$1.47 revenue$36,963,000

Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.
FT516 RMAT meeting with FDA scheduled for 3Q22 to discuss registrational pathways for relapsed/refractory aggressive B-cell lymphoma.
First patient dosed with FT536 CAR MICA/B NK cell product candidate for advanced solid tumors; multi-dose enrollment ongoing.
Janssen exercised commercial option for first iPSC-derived CAR NK collaboration program; first IND planned 2H22.
Expanded ONO collaboration: second solid tumor antigen program added, both CAR NK and CAR T candidates in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.